Demuphar SRL
Demuphar reported total assets of 978,525 € at the end of the 2025 financial year (annual accounts filed with the NBB on 10 Dec 2025).
The score of Demuphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +30 % Total assets 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Demuphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 30,155 € | ||||
| Equity | 315,914 € | ||||
| Cash | 7,670 € | ||||
| EBITDA | 74,516 € | ||||
| Total assets | 978,525 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 10 Dec 2025
- Year ended 30 Jun 2024filed on 22 Jan 2025
- Year ended 30 Jun 2023filed on 22 Jan 2024
- Year ended 30 Jun 2022filed on 29 Dec 2022
- Year ended 30 Jun 2021filed on 03 Jan 2022
Demuphar's financial analysis
- Solvency32.3%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Demuphar
Demuphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0415.077.054
- VAT number
- BE0415077054
- Peppol
- Registered · 0208:0415077054 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Jan 1975
- Registered office
- 9000 Ghent
- Latest accounts
- 2025 · filed on 10 Dec 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Demuphar (SRL) has been based in Ghent since 1975, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 30,155 € and equity of 315,914 €; its revenue is not published. Its solvency stands at 32.3%, below the median of its sector (44.0%).
Companies similar to Demuphar
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Bruggeman Retail sale of pharmaceutical products Ghent · balance sheet €1.17m
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- D'Haen Pharma Retail sale of pharmaceutical products Zottegem · balance sheet 987,565 €
- Akaption Retail sale of pharmaceutical products Braives · balance sheet 967,311 €
- Demaphar Retail sale of pharmaceutical products Mons · balance sheet 965,578 €
- G-PAS Holding Retail sale of pharmaceutical products Brasschaat · balance sheet 992,375 €
- PharmaLEDA Retail sale of pharmaceutical products Ixelles · balance sheet €1.01m
- Cassifarma Retail sale of pharmaceutical products Leuven · balance sheet 942,826 €
Frequently asked questions about Demuphar
What is the revenue of Demuphar?
Demuphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Demuphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0415077054 for Demuphar, if the company is VAT-registered. Its company number (CBE) is 0415.077.054.
Where is the registered office of Demuphar?
According to the CBE register, the registered office of Demuphar is in 9000 Ghent.
What is the equity of Demuphar?
At the close of the 2025 financial year, the equity of Demuphar amounts to 315,914 €, a solvency of 32.3% of total assets.
Who manages Demuphar?
The register lists 1 active mandates at Demuphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Demuphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →